Antitachycardic Therapy of ICD in Patients with Multiple Morphologies of Monomorphous Ventricular Tachycardia Refractory to Therapy

Dmitry B. Goncharik , Veronika Ch. Barsukevich , Larisa I. Plashchinskaya , Michail A. Zakhareuski

Cardiac Arrhythmias ›› 2022, Vol. 2 ›› Issue (4) : 43 -54.

PDF (2418KB)
Cardiac Arrhythmias ›› 2022, Vol. 2 ›› Issue (4) :43 -54. DOI: 10.17816/cardar112248
Case reports
research-article

Antitachycardic Therapy of ICD in Patients with Multiple Morphologies of Monomorphous Ventricular Tachycardia Refractory to Therapy

Author information +
History +
PDF (2418KB)

Abstract

The article presents a description of a clinical case of a patient with structural myocardial pathology (postinfarction cardiosclerosis) with recurrent paroxysmal sustained monomorphic ventricular tachycardia (VT) refractory to the nominal recommended ICD (implantable cardioverter defibrillator) settings; as well as discusses the shortcomings of existing standard algorithms for antitachycardia pacing (ATP) of implantable cardioverter defibrillators and potential ways to increase its efficiency. The refractoriness of recurrent paroxysms of ventricular tachycardia to ATP therapy increases the risk of repeated ICD shocks.

Despite the existence of universal recommendations for ICD programming and ATP therapy, there is a need in clinical practice for individualized ATP programming in patients refractory to nominal settings. Increasing the number of ATP series and changing algorithms enables to increase the efficiency of ATP up to 80–89%. Refractoriness to standard ATP settings may be also overcome by using alternative ATP pacing algorithms (Ramp, Burst-plus, or Ramp-plus instead of Burst), changing the pacing interval, ATP sequence duration, pacing type, and even adding 1–2 extra stimuli, as well as using data from the previous intracardiac electrophysiological heart test.

The presented clinical case of a patient with postinfarction cardiosclerosis and paroxysmal stable monomorphic VT (SM-VT) of several morphologies demonstrates that the arrhythmogenic substrate after myocardial infarction changes for a long time without new stenoses in large coronary arteries and without new episodes of acute coronary syndrome, as well as generates several different morphologies of VT from one scar (with different heart rates) and the effect on hemodynamics. The efficiency of early ATP pacing may differ for VT of various morphologies, which makes it reasonable to use alternative pacing algorithms (in addition to the standard Burst sequences recommended by the 2019 Consensus on ICD programming) and testing possible ATP algorithms during ablation of monomorphic VT, including during preventive VT ablation before ICD implantation.

Keywords

antitachycardia pacing / implantable cardioverter-defibrillator / monomorphic ventricular tachycardia / clinical case of VT refractoriness

Cite this article

Download citation ▾
Dmitry B. Goncharik, Veronika Ch. Barsukevich, Larisa I. Plashchinskaya, Michail A. Zakhareuski. Antitachycardic Therapy of ICD in Patients with Multiple Morphologies of Monomorphous Ventricular Tachycardia Refractory to Therapy. Cardiac Arrhythmias, 2022, 2(4): 43-54 DOI:10.17816/cardar112248

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Sweeney MO, Sherfesee L, DeGroot PJ, et al. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2010;7(3):353–360. DOI: 10.1016/j.hrthm.2009.11.027

[2]

Sweeney M.O., Sherfesee L., DeGroot P.J., et al. Differences in effects of electrical therapy type for ventricular arrhythmias on morta- lity in implantable cardioverter-defibrillator patients // Heart Rhythm. 2010. Vol. 7, No. 3. P. 353–360. DOI: 10.1016/j.hrthm.2009.11.027

[3]

Lindsay BD, Saksena S, Rothbart ST, et al. Prospective evaluation of a sequential pacing and high-energy bidirectional shock algorithm for transvenous cardioversion in patients with ventricular tachycardia. Circulation. 1987;76(3):601–609. DOI: 10.1161/01.cir.76.3.601

[4]

Lindsay B.D., Saksena S., Rothbart S.T., et al. Prospective evaluation of a sequential pacing and high-energy bidirectional shock algorithm for transvenous cardioversion in patients with ventricular tachycardia // Circulation. 1987. Vol. 76, No. 3. P. 601–609. DOI: 10.1161/01.cir.76.3.601

[5]

Stiles MK, Fauchier L, Morillo CA, Wilkoff BL. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal ICD programming and testing. Heart Rhythm. 2019;17(1):e220–e228. DOI: 10.1016/j.hrthm.2019.02.034

[6]

Stiles M.K., Fauchier L., Morillo C.A., Wilkoff B.L. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal ICD programming and testing // Heart Rhythm. 2019. Vol. 17, No. 1. P. e220–e228. DOI: 10.1016/j.hrthm.2019.02.034

[7]

Arenal A, Proclemer A, Kloppe A, et al. Different impact of long-detection interval and anti-tachycardia pacing in reducing unnecessary shocks: data from the ADVANCE III trial. Europace. 2016;18(11):1719–1725. DOI: 10.1093/europace/euw032

[8]

Arenal A., Proclemer A., Kloppe A., et al. Different impact of long-detection interval and anti-tachycardia pacing in reducing unnecessary shocks: data from the ADVANCE III trial // Europace. 2016. Vol. 18, No. 11. Р. 1719–1725. DOI: 10.1093/europace/euw032

[9]

Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation. 2001;104(7):796–801. DOI: 10.1161/hc3101.093906

[10]

Wathen M.S., Sweeney M.O., DeGroot P.J., et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease // Circulation. 2001. Vol. 104, No. 7. P. 796–801. DOI: 10.1161/hc3101.093906

[11]

Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105(5):589–594. DOI: 10.1161/hc0502.103330

[12]

Schron E.B., Exner D.V., Yao Q., et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks // Circulation. 2002. Vol. 105, No. 5. P. 589–594. DOI: 10.1161/hc0502.103330

[13]

Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008;359:1009–1017. DOI: 10.1056/NEJMoa071098

[14]

Poole J.E., Johnson G.W., Hellkamp A.S., et al. Prognostic importance of defibrillator shocks in patients with heart failure // N Engl J Med. 2008. Vol. 359. P. 1009–1017. DOI: 10.1056/NEJMoa071098

[15]

Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. DOI: 10.1093/eurheartj/ehac262

[16]

Zeppenfeld K., Tfelt-Hansen J., de Riva M., et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death // Eur Heart J. 2022. Vol. 43, No. 40. P. 3997–4126. DOI: 10.1093/eurheartj/ehac262

[17]

Kloppe A, Proclemer A, Arenal A, et al. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial. Circulation. 2014;130(4):308–314. DOI: 10.1161/CIRCULATIONAHA.114.009468

[18]

Kloppe A., Proclemer A., Arenal A., et al. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial // Circulation. 2014. Vol. 130, No. 4. P. 308–314. DOI: 10.1161/CIRCULATIONAHA.114.009468

[19]

Stiles MK, Fauchier L, Morillo CA, Wilkoff BL. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal ICD programming and testing. Heart Rhythm. 2019;17(1):e220–e228. DOI: 10.1016/j.hrthm.2019.02.034

[20]

Stiles M.K., Fauchier L., Morillo C.A., Wilkoff B.L. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal ICD programming and testing // Heart Rhythm. 2019. Vol. 17, No. 1. P. e220–e228. DOI: 10.1016/j.hrthm.2019.02.034

[21]

Joung B, Lexcen DR, Ching CK, et al. Antitachycardia Pacing (ATP) programing strategies further unnecessary ICD Shocks. Presented at APHRS; Oct 2018; Taipei, Taiwan. Chinmai Parikh, ATP programming in US ICD CareLink patients Data on File. 2019.

[22]

Joung B., Lexcen D.R., Ching C.K., et al. Antitachycardia Pacing (ATP) programing strategies further unnecessary ICD Shocks. Presented at APHRS; Oct 2018; Taipei, Taiwan. Chinmai Parikh, ATP programming in US ICD CareLink patients Data on File. 2019.

[23]

Joung B, Lexcen DR, Ching CK, et al. Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocks. Heart Rhythm. 2020;17(1):98–105. DOI: 10.1016/j.hrthm.2019.07.027

[24]

Joung B., Lexcen D.R., Ching C.K., et al. Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocks // Heart Rhythm. 2020. Vol. 17, No. 1. P. 98–105. DOI: 10.1016/j.hrthm.2019.07.027

[25]

Strik M, Ramirez FD, Welte N, et al. Progressive implantable cardioverter-defibrillator therapies for ventricular tachycardia: The efficacy and safety of multiple bursts, ramps, and low-energy shocks. Heart Rhythm. 2020;17(12):2072–2077. DOI: 10.1016/j.hrthm.2020.07.032

[26]

Strik M., Ramirez F.D., Welte N., et al. Progressive implantable cardioverter-defibrillator therapies for ventricular tachycardia: The efficacy and safety of multiple bursts, ramps, and low-energy shocks // Heart Rhythm. 2020. Vol. 17, No. 12. P. 2072–2077. DOI: 10.1016/j.hrthm.2020.07.032

[27]

Gulizia MM, Piraino L, Scherillo M, et al. A Randomized Study to Compare Ramp Versus Burst Antitachycardia Pacing Therapies to Treat Fast Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter Defibrillators. The PITAGORA ICD Trial. Circ Arrhythm Electrophysiol. 2009;2(2):146–153. DOI: 10.1161/CIRCEP.108.804211

[28]

Gulizia M.M., Piraino L., Scherillo M., et al. A Randomized Study to Compare Ramp Versus Burst Antitachycardia Pacing Therapies to Treat Fast Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter Defibrillators. The PITAGORA ICD Trial // Circ Arrhythm Electrophysiol. 2009. Vol. 2, No. 2. P. 146–153. DOI: 10.1161/CIRCEP.108.804211

[29]

Schukro C, Leitner L, Siebermair J, et al. Impact of accelerated ventricular tachyarrhythmias on mortality in patients with implantable cardioverterdefibrillator therapy. Int J Cardiol. 2013;167(6): 3006–3010. DOI: 10.1016/j.ijcard.2012.09.015

[30]

Schukro C., Leitner L., Siebermair J., et al. Impact of accelerated ventricular tachyarrhythmias on mortality in patients with implantable cardioverterdefibrillator therapy // Int J Cardiol. 2013. Vol. 167, No. 6. P. 3006–3010. DOI: 10.1016/j.ijcard.2012.09.015

[31]

Swenson DJ, Taepke RT, Blauer JJE, et al. Direct comparison of a novel antitachycardia pacing algorithm against present methods using virtual patient modeling. Heart Rhythm. 2020;17(9):1602–1608. DOI: 10.1016/j.hrthm.2020.05.009

[32]

Swenson D.J., Taepke R.T., Blauer J.J.E., et al. Direct comparison of a novel antitachycardia pacing algorithm against present methods using virtual patient modeling // Heart Rhythm. 2020. Vol. 17, No. 9. P. 1602–1608. DOI: 10.1016/j.hrthm.2020.05.009

RIGHTS & PERMISSIONS

Eco-Vector

PDF (2418KB)

113

Accesses

0

Citation

Detail

Sections
Recommended

/